​

Avidity Biosciences (RNA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Avidity Biosciences Revenue Highlights

Latest Revenue (Y)

$10.90M

Latest Revenue (Q)

$2.04M

Main Segment (Y)

Reportable Segment

Avidity Biosciences Revenue by Period

Avidity Biosciences Revenue by Year

DateRevenueChange
2024-12-31$10.90M13.99%
2023-12-31$9.56M3.64%
2022-12-31$9.22M-1.09%
2021-12-31$9.33M37.41%
2020-12-31$6.79M192.67%
2019-12-31$2.32M511.87%
2018-12-31$379.00K-

Avidity Biosciences generated $10.90M in revenue during NA 2024, up 13.99% compared to the previous quarter, and up 469.90% compared to the same period a year ago.

Avidity Biosciences Revenue by Quarter

DateRevenueChange
2024-06-30$2.04M-42.28%
2024-03-31$3.54M61.56%
2023-12-31$2.19M-22.18%
2023-09-30$2.82M21.68%
2023-06-30$2.32M3.72%
2023-03-31$2.23M-19.36%
2022-12-31$2.77M11.56%
2022-09-30$2.48M13.96%
2022-06-30$2.18M21.34%
2022-03-31$1.79M-3.08%
2021-12-31$1.85M-14.38%
2021-09-30$2.16M-17.03%
2021-06-30$2.61M-3.59%
2021-03-31$2.70M26.24%
2020-12-31$2.14M22.68%
2020-09-30$1.75M13.30%
2020-06-30$1.54M13.48%
2020-03-31$1.36M-6.02%
2019-12-31$1.45M122.31%
2019-09-30$650.00K190.18%
2019-06-30$224.00K100.00%
2019-03-31--

Avidity Biosciences generated $2.04M in revenue during Q2 2024, up -42.28% compared to the previous quarter, and up 91.58% compared to the same period a year ago.

Avidity Biosciences Revenue Breakdown

Avidity Biosciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Reportable Segment$10.90M

Avidity Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).

Avidity Biosciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARVNArvinas$263.40M$102.40M
SWTXSpringWorks Therapeutics$191.59M$59.73M
DAWNDay One Biopharmaceuticals$131.16M$20.07M
STOKStoke Therapeutics$36.55M$4.89M
RNAAvidity Biosciences$10.90M$2.04M
RLAYRelay Therapeutics$10.01M-
IGMSIGM Biosciences$2.68M$516.00K
CGEMCullinan Oncology--
AKROAkero Therapeutics--
BDTXBlack Diamond Therapeutics--
PTGXProtagonist Therapeutics-$4.67M
RVMDRevolution Medicines--
MLYSMineralys Therapeutics--
PLRXPliant Therapeutics--
PASGPassage Bio--

RNA Revenue FAQ

What is Avidity Biosciences’s yearly revenue?

Avidity Biosciences's yearly revenue for 2024 was $10.9M, representing an increase of 13.99% compared to 2023. The company's yearly revenue for 2023 was $9.56M, representing an increase of 3.64% compared to 2022. RNA's yearly revenue for 2022 was $9.22M, representing a decrease of -1.09% compared to 2021.

What is Avidity Biosciences’s quarterly revenue?

Avidity Biosciences's quarterly revenue for Q2 2024 was $2.04M, a -42.28% decrease from the previous quarter (Q1 2024), and a -11.70% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $3.54M, a 61.56% increase from the previous quarter (Q4 2023), and a 58.67% increase year-over-year (Q1 2023). RNA's quarterly revenue for Q4 2023 was $2.19M, a -22.18% decrease from the previous quarter (Q3 2023), and a -20.80% decrease year-over-year (Q4 2022).

What is Avidity Biosciences’s revenue growth rate?

Avidity Biosciences's revenue growth rate for the last 3 years (2022-2024) was 18.14%, and for the last 5 years (2020-2024) was 60.56%.

What are Avidity Biosciences’s revenue streams?

Avidity Biosciences's revenue streams in c 24 are Reportable Segment

What is Avidity Biosciences’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Avidity Biosciences was Reportable Segment. This segment made a revenue of $10.9M, representing 100.00% of the company's total revenue.